4.3 Article

Mitral valve-in-valve and valve-in-ring procedures: Midterm outcomes in a French nationwide registry

Journal

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
Volume 99, Issue 6, Pages 1829-1838

Publisher

WILEY
DOI: 10.1002/ccd.30161

Keywords

heart failure; mitral valve disease; paravalvular leak; percutaneous intervention; percutaneous valve therapy; structural heart disease intervention

Ask authors/readers for more resources

This study reports the contemporary outcomes of patients who underwent transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis. The results demonstrate the safety and efficacy of the procedure, with higher risk of procedural complications in the valve-in-ring group. The presence of paravalvular leak is associated with significantly worse midterm prognosis.
Objectives Report contemporary outcomes in patients included in the Mitragister registry and treated with transcatheter mitral valve implantation for failed surgical annuloplasty rings or deteriorated bioprosthesis. Background Midterm survival rates have been reported, but little is known about contemporary morbimortality endpoints. Methods The primary safety outcome was the technical success rate. The primary efficacy composite endpoint was a composite of cardiovascular mortality and heart failure hospitalizations. Results From 2016 to 2021, 102 patients (median age: 81 [74;84] years, 61% female, Euroscore II 11.0% [7.8;16.0]) undergoing valve-in-valve (ViV; n = 89) or valve-in-ring (ViR; n = 13) procedures were consecutively included. At baseline, ViR group patients had worse left ventricular ejection fraction (50% vs. 60%; p = 0.004) and more frequently severe regurgitation (46% vs. 15%; p = 0.014). The primary safety outcome was 95%: 77% and 98% in the ViR and ViV populations, respectively, (p = 0.014). At intermediate follow-up (6-12 months) clinical improvement was notable, 88% of the patients were in NYHA class <= II (vs. 25% at baseline; p < 0.001). At a mean follow-up of 17.1 +/- 11.0 months, the primary efficacy composite reached 27%. By multivariate analysis, paravalvular leak (PVL) was the only independent predictor (hazard ratio: 2.39, 95% confidence interval: 1.08-5.29; p = 0.031) while ViR was not found statistically associated (p = 0.456). Conclusions This study confirms the safety and efficacy of the mitral ViV procedure. ViR patients appear at higher risk of procedural complications. The presence of PVL could be associated with markedly worse midterm prognosis. Whatever the intervention, procedural strategies to reduce PVL incidence remain to be assessed to prevent latter adverse outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available